Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen L. Mayo
AddedFeb 19, 2024
UpdatedMay 31, 2026
Stephen L. Mayo

Stephen L. Mayo

Board Member, Allogene Therapeutics

LinkedInThe Org

Stephen L. Mayo's Career

Allogene Therapeutics
Allogene Therapeutics

South San Francisco, CA, US

Board Member· Board
Sarepta Therapeutics
Sarepta Therapeutics

Cambridge, MA, US

Board Member· Board
Merck & CO INC Cedear EAC 5 RE
Merck & CO INC Cedear EAC 5 RE

Rahway, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen L. Mayo's Career

Allogene Therapeutics
Allogene Therapeutics
Public$781.8M3612017South San Francisco, CA, US
Board Member· Board

Leadership at Allogene Therapeutics

David ChangDavid ChangFounder
Liz BarrettLiz BarrettBoard Member
Debbie MessemerDebbie MessemerBoard Member
Owen WitteOwen WitteBoard Member
John DeYoungJohn DeYoungBoard Member
Franz HumerFranz HumerBoard Member
Sarepta Therapeutics
Sarepta Therapeutics
Public$1.4B1.2k1980Cambridge, MA, US
Board Member· Board

Leadership at Sarepta Therapeutics

Kathy Behrens WilseyKathy Behrens WilseyBoard Member
Mary Ann GrayMary Ann GrayBoard Member
Marwan FawazMarwan FawazFounder
Doug IngramDoug IngramBoard Member
Hans WigzellHans WigzellBoard Member

Similar to Sarepta Therapeutics

SonoTheraSonoTheraSouth San Francisco, CA, USGenetic Therapiesest. 2021SonoTheraSouth San Francisco, CA, US · est. 2021

SonoThera is a biotechnology company developing ultrasound-mediated nonviral genetic medicines for diseases including Duchenne muscular dystrophy and hemophilia A.

Series B · $185.8M50
Solid BiosciencesSolid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Editas MedicineEditas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226
Merck & CO INC Cedear EAC 5 RE
Merck & CO INC Cedear EAC 5 RE
Public$8.2M69k1891Rahway, NJ, US
Board Member· Board

Recent news

AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.TechCrunch · 2026
Qualifyze swallows $54M to improve pharmaceutical supply chainsTechCrunch · 2024
Observability platform Better Stack secures $10M cash infusionTechCrunch · 2024

Leadership at Merck & CO INC Cedear EAC 5 RE

Inge ThulinInge ThulinBoard Member
Kenneth FrazierKenneth FrazierBoard Member
Patricia RussoPatricia RussoBoard Member
Paul RothmanPaul RothmanBoard Member
Pamela CraigPamela CraigBoard Member
Tom GlocerTom GlocerBoard Member

Stephen L. Mayo's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Stephen L. Mayo

Nimesh JhaveriNimesh JhaveriBoard Member · Illuminate HealthJacques TapieroJacques TapieroBoard Member · McCormickJack PartridgeJack PartridgeBoard Member · GlobalWorxShawn SchukarShawn SchukarBoard Member · AmerenDavid AninowskyDavid AninowskyBoard Member · ConstantMichael SchwabMichael SchwabBoard Member · M&T